The rise of Sildenafil initially sparked a surge for pharma, nevertheless recent changes present a uncertain picture for shareholders. Generic alternatives are eating into revenue, and persistent litigation add further https://imogenlfol863306.fare-blog.com/41584874/sildenafil-and-the-pharmaceutical-industry-a-volatile-bet